Avanos Q2 sales $169.4M, adjusted EPS $0.24; FY2023 adjusted EPS guidance $1.05-$1.15

AVANOS MEDICAL, INC.

2023-Q2 EPS reported -$1.47 revenue$328,700,000

Q2 net sales $169.4M (-0.9% YoY); net loss $4.3M vs net income $4.8M a year ago.
Adjusted diluted EPS $0.24 vs $0.26; adjusted EBITDA flat at $22.9M.
Closed Diros Technologies acquisition (RFA) in July; recorded $72.3M impairment on Respiratory Health divestiture.
UK NICE recommends RFA for osteoarthritic knee pain, potentially improving Pain Management reimbursement.
FY2023 outlook: adjusted EPS $1.05-$1.15, adjusted gross margin >59%, H2 organic growth low single-digit.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

AVANOS MEDICAL, INC. reported financial results for the three and six months ended June 30, 2023.

Period: the three and six months ended June 30, 2023
Result: reported results

Exact text from the filing

Avanos Medical, Inc. (the “Company”) announced its results of operations for the three and six months ended June 30, 2023 in a press release dated August 9, 2023.

View on SEC.gov

Browse all earnings releases →

AVANOS MEDICAL, INC. filing history →

Source: SEC EDGAR

accession 0001606498-23-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.